Overview

Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
In this prospective study, 68Ga-PSMA integrated PET/MR imaging was applied for the diagnosis and staging of hepatocellular carcinoma (HCC). The detection and diagnostic performance of 68Ga-PSMA PET/MR for HCC was evaluated in comparison with the gold standard of puncture biopsy or postoperative pathology. The aim is to make up for the deficiency in FDG PET imaging in the diagnosis and staging of HCC.
Phase:
N/A
Details
Lead Sponsor:
Wuhan Union Hospital, China
Treatments:
Gallium 68 PSMA-11